News & Events

AGM Statement

AGM Statement

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global specialty pharmaceuticals business, is holding its Annual General Meeting (“AGM”) at 10.00am today at Instinctif Partners’ offices, 65 Gresham Street, London EC2 7NQ.

At the meeting Peter Allen, Clinigen’s Chairman, and Peter George, Group Chief Executive Officer, will cover the following areas:

This has been a strategically transformational year for the Group. During the year, Clinigen has doubled the size of the business, strengthened its global capabilities, become the global market leader in the ethical supply of unlicensed medicines and continued the revitalization of its speciality products portfolio.

Through the acquisition of Idis, the Group has extended its unique, synergistic business model and created a better balanced portfolio of businesses. Clinigen is now the market leader in the $5+ billion unlicensed medicine supply sector and the $2 billion clinical trial supply market. The proposed acquisition of Link, due to complete shortly, will also substantially broaden the Group’s international distribution footprint across the AAA region - Asia, Africa and Australasia.

As reported at Clinigen’s full year results in September, all of its newer specialty pharma assets - Cardioxane, Savene and Ethyol – continue to progress to plan. The lifting of the EMA Article 31 referral for Cardioxane also remains on track.

Having completed the CFO handover period, described previously, Robin Sibson will step down from the role of CFO after the AGM and Martin Abell will now assume that role with immediate effect. The Board welcomes Martin and thanks Robin for the important role that he has played in the success and development of the Group. Robin will continue to work with the Group in his new role as a Non-Executive Director of Clinigen.

Clinigen’s strong financial performance demonstrates its strengthened international position in growing markets. The Group is on track in advancing its underlying philosophy of getting the right drug to the right patient at the right time, regardless of where they are in the world.

- ENDS -

Issued for and on behalf of Clinigen Group by Instinctif Partners.

For more information please contact:

Clinigen Group plc
Peter George, Group Chief Executive Officer
Shaun Chilton, Group Deputy Chief Executive Officer
Martin Abell, Group Chief Financial Officer
Tel: +44 (0) 1283 495010

Numis Securities Limited
Michael Meade/Freddie Barnfield (Nominated Adviser)
James Black/Tom Ballard  (Corporate Broking)
Tel: +44 (0) 20 7260 1000

Peel Hunt LLP
James Steel/Jock Maxwell Macdonald
Tel: +44 (0) 20 7418 8900

Instinctif Partners
Melanie Toyne-Sewell/Jayne Crook/Emma Barlow
Tel: +44 (0) 20 7457 2020

Notes To Editors

About Clinigen Group
Clinigen Group is a global pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time. The Group consists of four synergistic businesses that provide medicines to patients with unmet medical need; Clinigen CTS manages the supply of commercial medicines for clinical trials; Idis Managed Access runs early access programs for Clinigen’s own and other companies' portfolios; Idis Global Access works directly with healthcare providers to enable ethical compliant access to unlicensed medicines and Clinigen SP acquires and markets our own portfolio of hospital only niche medicines.

Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need.

For more information, please visit

back to news


Melanie Toyne-SewellManaging Partner